scholarly journals HIV program outcomes for Jamaica before and after “Treat All”: A population-based study using the national treatment services database

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255781
Author(s):  
Anya Cushnie ◽  
Ralf Reintjes ◽  
Susanna Lehtinen-Jacks ◽  
J. Peter Figueroa

Objective The study aims to assess changes in HIV treatment outcomes for Jamaica after the implementation of the WHO Treat All strategy in January 2017, as well as identify variables associated with clinical stage at diagnosis and viral load status, in order to understand implications for enhancing the HIV clinical cascade and boosting progress towards the UNAIDS 90-90-90 targets. Method This is a population-based study using the National Treatment Service Information System. The sample consists of persons 15 years and older, placed on treatment before and after Treat All was implemented, across all 4 regional health authorities in Jamaica. Patients were assessed for two binary outcomes: 1. stage at HIV diagnosis (early/baseline CD4 cell count ≧350 cells/mm3, or late/ baseline CD4 <350 cells/mm3), 2. viral load status achieved after ART initiation (suppressed/<1000 copies/ml or non-suppressed/ ≥1000 copies/ml). Categorical variables: age/years, gender and health regions, were investigated using multivariable logistic regression. Adjusted odds ratios and 95% confidence intervals are reported. Results After Treat All, there was an increase in median baseline CD4 results as the proportion of late diagnoses decreased from 60% to 39%. There was a small increase in viral suppression from 76% to 80%, a decrease in baseline viral load testing from 61% to 46% and an increase in the uptake of first viral load testing after starting treatment from 13% to 19%. Males and persons 40+ years had higher odds of late diagnosis before and after Treat All. Conclusion Jamaica’s HIV program outcomes have improved after Treat All was implemented. ART initiation time significantly decreased. Early diagnosis, viral load testing uptake and viral suppression increased. However, there is a need to implement targeted testing for men and persons over 40 years to decrease the frequency of late diagnosis.

1999 ◽  
Vol 30 (2) ◽  
pp. 102-108
Author(s):  
Patricia Bereck Weikersheimer

2011 ◽  
Vol 14 (1) ◽  
pp. 23-23 ◽  
Author(s):  
Jane Greig ◽  
Philipp du Cros ◽  
Derryck Klarkowski ◽  
Clair Mills ◽  
Steffen Jørgensen ◽  
...  

2010 ◽  
Vol 201 (s1) ◽  
pp. S27-S36 ◽  
Author(s):  
Adrian Puren ◽  
Jay L. Gerlach ◽  
Bernhard H. Weigl ◽  
David M. Kelso ◽  
Gonzalo J. Domingo

Author(s):  
Tea Lallukka ◽  
Jenni Ervasti ◽  
Erik Lundström ◽  
Ellenor Mittendorfer‐Rutz ◽  
Emilie Friberg ◽  
...  

2010 ◽  
Vol 14 (7) ◽  
pp. 852-858 ◽  
Author(s):  
M. Barton ◽  
S. Wasfy ◽  
D. Hébert ◽  
A. Dipchand ◽  
A. Fecteau ◽  
...  

1999 ◽  
Vol 123 (11) ◽  
pp. 1011-1014
Author(s):  
Frederick S. Nolte

Abstract Quantitative human immunodeficiency virus (HIV) type 1 RNA tests have been essential tools in increasing our understanding of HIV pathogenesis and antiretroviral therapy. The plasma HIV RNA level is among the most powerful predictive tests in modern medicine for disease progression and has rapidly become the standard of practice for guiding clinicians in initiating, monitoring, and changing antiretroviral therapy. In this article the scientific rationale and clinical indications for viral load testing in HIV infection are reviewed.


Sign in / Sign up

Export Citation Format

Share Document